Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsColorado Rocky Mountain Enzyme Prior Auth | OpenPa…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedColorado Rocky Mountain Health PlansPolicy CSPA2026D0052A

    Medical Therapies for Enzyme Deficiencies (for Pennsylvania Only)

    Customize your policy alerts

    Sign up for Colorado Rocky Mountain Health Plans Policy CSPA2026D0052A alerts

    Get alerted when Policy CSPA2026D0052A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical benefit drug coverage and prior authorization for specified enzyme replacement and related therapies for members in Pennsylvania.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyMedical Therapies for Enzyme Deficiencies (for Pennsylvania Only)
    Policy CodePolicy CSPA2026D0052A
    Change TypeModified
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with product-specific diagnosis confirmation, accepted dosing support, and applicable clinical response documentation.
    SourceLink
    POLICY UPDATE CHANGES

    Added Avlayah (tividenofusp alfa-eknm) and Loargys (pegzilarginase-nbln) to the applicable medical therapies for enzyme deficiencies.

    Added initial and continuation coverage criteria for Avlayah for neurologic manifestations of Hunter syndrome and for Loargys for hyperargininemia caused by arginase 1 deficiency.

    Revised the dosing criterion to require dosing consistent with FDA-approved labeling, nationally recognized compendia, or peer-reviewed medical literature.

    Removed initial-therapy requirements for clinical signs and symptoms of disease from the Aldurazyme, Elaprase, Kanuma, and Lumizyme criteria.

    Added a requirement that Elaprase not be used in combination with Avlayah for treatment of MPS II.

    Added HCPCS code J1757 and ICD-10 diagnosis code E76.1 for Avlayah, and HCPCS code J1818 and ICD-10 diagnosis code E27.21 for Loargys.

    2New enzyme therapies
    4New applicable codes
    12 monthsMaximum authorization period
    PAApplicable state

    Therapy-Specific Coverage Criteria

    Aldurazyme — MPS I

    Covered when all applicable initial or continuation criteria are met.

    Initial therapy: MPS I is confirmed as Hurler, Hurler-Scheie, or Scheie syndrome by deficient or absent alpha-L-iduronidase activity or molecular genetic testing; dosing follows FDA-approved labeling, nationally recognized compendia, or peer-reviewed medical literature; and initial authorization is no more than 12 months.12 months
    Continuation therapy: The patient previously received laronidase, experienced a positive clinical response, dosing follows accepted clinical sources, and reauthorization is no more than 12 months.12 months

    Avlayah — MPS II neurologic manifestations

    Covered when all applicable initial or continuation criteria are met.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyMedical Therapies for Enzyme Deficiencies (for Pennsylvania Only)
    Policy CodePolicy CSPA2026D0052A
    Change TypeModified
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with product-specific diagnosis confirmation, accepted dosing support, and applicable clinical response documentation.
    SourceLink
    On This Page
    Therapy-Specific Coverage CriteriaApplicable Codes and Clinical ThresholdsAuthorization, Documentation, and Denial RisksPolicy BackgroundDisease and Therapy DefinitionsInitial Therapy RequirementsContinuation and Reauthorization RequirementsTreatment Switching RequirementsAuthorization Period Limits
    Initial therapy: MPS II is confirmed by deficient iduronate 2-sulfatase activity in fibroblasts or leukocytes with normal activity of another sulfatase, or by molecular genetic testing; Avlayah is not used with Elaprase; dosing follows accepted clinical sources; and initial authorization is no more than 12 months.12 months
    Continuation therapy: The patient previously received tividenofusp alfa, experienced a positive clinical response, Avlayah is not used with Elaprase, dosing follows accepted clinical sources, and reauthorization is no more than 12 months.12 months

    Elaprase — MPS II

    Covered when all applicable initial or continuation criteria are met.

    Initial therapy: MPS II is confirmed by deficient iduronate 2-sulfatase activity in fibroblasts or leukocytes with normal activity of another sulfatase, or by molecular genetic testing; Elaprase is not used with Avlayah; dosing follows accepted clinical sources; and initial authorization is no more than 12 months.12 months
    Continuation therapy: The patient previously received idursulfase, experienced a positive clinical response, Elaprase is not used with Avlayah, dosing follows accepted clinical sources, and reauthorization is no more than 12 months.12 months

    Elfabrio — Fabry disease

    Covered when all applicable initial or continuation criteria are met.

    Initial therapy: Fabry disease is confirmed by alpha-galactosidase A activity below 5% of the mean or molecular genetic testing; clinical signs and symptoms are present; Elfabrio is not combined with another Fabry disease-modifying therapy; dosing follows accepted clinical sources; and initial authorization is no more than 12 months.Alpha-galactosidase A activity < 5% of mean; 12 months
    Continuation therapy: The patient previously received pegunigalsidase alfa, experienced a positive clinical response, Elfabrio is not combined with another Fabry disease-modifying therapy, dosing follows accepted clinical sources, and reauthorization is no more than 12 months.12 months

    Fabrazyme — Fabry disease

    Covered when all applicable initial or continuation criteria are met.

    Initial therapy: Fabry disease is confirmed by alpha-galactosidase A activity below 5% of the mean or molecular genetic testing; clinical signs and symptoms are present; Fabrazyme is not combined with another Fabry disease-modifying therapy; dosing follows accepted clinical sources; and initial authorization is no more than 12 months.Alpha-galactosidase A activity < 5% of mean; 12 months
    Continuation therapy: The patient previously received agalsidase beta, experienced a positive clinical response, Fabrazyme is not combined with another Fabry disease-modifying therapy, dosing follows accepted clinical sources, and reauthorization is no more than 12 months.12 months

    Kanuma — LAL-D

    Covered when all applicable initial or continuation criteria are met.

    Initial therapy: LAL-D, Wolman disease, or cholesteryl ester disease is confirmed by deficient lysosomal acid lipase activity on dried blood spot testing or molecular genetic testing involving LIPA; dosing follows accepted clinical sources; and initial authorization is no more than 12 months.12 months
    Continuation therapy: The patient previously received sebelipase alfa, experienced a positive clinical response, dosing follows accepted clinical sources, and reauthorization is no more than 12 months.12 months

    Lamzede — alpha-mannosidosis

    Covered when all applicable initial or continuation criteria are met.

    Initial therapy: Alpha-mannosidosis is confirmed by alpha-mannosidase activity below 10% of the laboratory-specific normal mean or MAN2B1 molecular testing; clinical signs and symptoms are present; Lamzede is not used for central nervous system manifestations; dosing follows accepted clinical sources; and initial authorization is no more than 12 months.Alpha-mannosidase activity < 10%; 12 months
    Continuation therapy: The patient previously received velmanase alfa, experienced a positive clinical response, dosing follows accepted clinical sources, and reauthorization is no more than 12 months.12 months

    Sebelipase alfa initial and continuation therapy

    Covered when all applicable initial or continuation criteria are met.

    Initial therapy: The applicable enzyme deficiency and clinical eligibility are established; dosing follows FDA-approved labeling, nationally recognized compendia, or peer-reviewed medical literature; and initial authorization is no more than 12 months.12 months
    Continuation therapy: The patient previously received sebelipase alfa, experienced a positive clinical response such as improved symptoms or liver function tests, cholesterol, or triglycerides, dosing follows accepted clinical sources, and reauthorization is no more than 12 months.12 months

    Lamzede: alpha-mannosidosis

    Covered when all applicable initial or continuation criteria are met.

    Initial therapy: Alpha-mannosidosis is confirmed by alpha-mannosidase activity below 10% of the laboratory-specific normal mean or MAN2B1 molecular testing; clinical signs and symptoms are present; Lamzede is not used for central nervous system manifestations; dosing follows accepted clinical sources; and initial authorization is no more than 12 months.Alpha-mannosidase activity < 10%; 12 months
    Continuation therapy: The patient previously received velmanase alfa-tycv, experienced a positive clinical response such as improved motor or pulmonary function, dosing follows accepted clinical sources, and reauthorization is no more than 12 months.12 months

    Loargys: hyperargininemia

    Covered when all applicable initial or continuation criteria are met.

    Initial therapy: Hyperargininemia due to arginase 1 deficiency is confirmed by absent or deficient arginase 1 activity or ARG1 genetic variants; clinical signs and symptoms are present; dosing follows accepted clinical sources; and initial authorization is no more than 12 months.12 months
    Continuation therapy: The patient previously received pegzilarginase, experienced a positive clinical response such as improved motor or pulmonary function, dosing follows accepted clinical sources, and reauthorization is no more than 12 months.12 months

    Lumizyme: infantile-onset or late-onset Pompe disease

    Covered when either complete initial-therapy pathway is met.

    Initial therapy disease-onset pathways

    • Infantile-onset Pompe disease is confirmed by acid alpha-glucosidase activity below 1% of the laboratory-specific normal mean in skin fibroblasts or GAA molecular testing; Lumizyme is not combined with another disease-modifying Pompe enzyme therapy; dosing follows accepted clinical sources; and initial authorization is no more than 12 months.GAA activity < 1%; 12 months
    • Late-onset Pompe disease is confirmed by acid alpha-glucosidase activity below 40% of the laboratory-specific normal mean in lymphocytes, fibroblasts, or muscle or GAA molecular testing; clinical signs and symptoms are present; Lumizyme is not combined with another disease-modifying Pompe enzyme therapy; dosing follows accepted clinical sources; and initial authorization is no more than 12 months.GAA activity < 40%; 12 months

    Lumizyme continuation

    Covered when all of the following are met.

    Continuation therapy: The patient previously received alglucosidase alfa, experienced a positive clinical response such as improved respiratory or cardiac function or endurance, is not receiving Lumizyme with another disease-modifying Pompe enzyme therapy, dosing follows accepted clinical sources, and reauthorization is no more than 12 months.12 months

    Mepsevii: MPS VII

    Covered when all applicable initial or continuation criteria are met.

    Initial therapy: MPS VII is confirmed by deficient beta-glucuronidase activity in fibroblasts or leukocytes or GUSB molecular testing; clinical signs and symptoms are present; dosing follows accepted clinical sources; and initial authorization is no more than 12 months.12 months
    Continuation therapy: The patient previously received vestronidase alfa-vjbk, experienced a positive clinical response, dosing follows accepted clinical sources, and reauthorization is no more than 12 months.12 months

    Naglazyme: MPS VI

    Covered when all applicable initial or continuation criteria are met.

    Initial therapy: MPS VI is confirmed by deficient N-acetylgalactosamine 4-sulfatase activity in fibroblasts or leukocytes or ASB molecular testing; clinical signs and symptoms are present; dosing follows accepted clinical sources; and initial authorization is no more than 12 months.12 months
    Continuation therapy: The patient previously received galsulfase, experienced a positive clinical response, dosing follows accepted clinical sources, and reauthorization is no more than 12 months.12 months

    Nexviazyme: late-onset Pompe disease

    Covered when all applicable initial or continuation criteria are met.

    Initial therapy: Late-onset Pompe disease is confirmed by GAA activity below 40% of the laboratory-specific normal mean in lymphocytes, fibroblasts, or muscle or GAA molecular testing; clinical signs and symptoms are present; Nexviazyme is not combined with another disease-modifying Pompe enzyme therapy; dosing follows accepted clinical sources; and initial authorization is no more than 12 months.GAA activity < 40%; 12 months
    Continuation therapy: The patient previously received avalglucosidase alfa-ngpt, experienced a positive clinical response, is not receiving Nexviazyme with another disease-modifying Pompe enzyme therapy, dosing follows accepted clinical sources, and reauthorization is no more than 12 months.12 months

    Nulibry: MoCD type A

    Covered when all applicable initial or continuation criteria are met.

    Initial therapy: MoCD type A is confirmed by deficient sulfite oxidase activity in fibroblasts or MOCS1 molecular testing; specified clinical signs or symptoms are present within the first 28 days after birth; dosing follows accepted clinical sources; and initial authorization is no more than 12 months.Within first 28 days after birth; 12 months
    Continuation therapy: The patient previously received fosdenopterin, experienced a positive clinical response, dosing follows accepted clinical sources, and reauthorization is no more than 12 months.12 months

    Pombiliti plus Opfolda: late-onset Pompe disease

    Covered when all applicable initial or continuation criteria are met.

    Initial therapy: Late-onset Pompe disease is confirmed by GAA activity below 40% of the laboratory-specific normal mean in lymphocytes, fibroblasts, or muscle or GAA molecular testing; clinical signs and symptoms are present; the provider attests that current ERT is not improving the patient and will be stopped; weight is at least 40 kg; Pombiliti is prescribed with oral Opfolda; no other disease-modifying Pompe enzyme therapy is used concurrently; dosing follows accepted clinical sources; and initial authorization is no more than 12 months.GAA activity < 40%; weight ≥ 40 kg; 12 months
    Continuation therapy: The patient previously received Pombiliti, experienced a positive clinical response to Pombiliti plus Opfolda, continues Opfolda, is not receiving another disease-modifying Pompe enzyme therapy, dosing follows accepted clinical sources, and reauthorization is no more than 12 months.12 months

    Pombiliti initial and continuation therapy

    Covered when all applicable initial or continuation criteria are met.

    Initial therapy: Late-onset Pompe disease is confirmed by GAA activity below 40% of the laboratory-specific normal mean in lymphocytes, fibroblasts, or muscle or GAA molecular testing; clinical signs and symptoms are present; current ERT is not improving the patient and will be stopped; weight is at least 40 kg; Pombiliti is prescribed with oral Opfolda; no other disease-modifying Pompe enzyme therapy is used concurrently; and dosing follows accepted sources.GAA activity < 40%; weight ≥ 40 kg
    Continuation therapy: The patient previously received Pombiliti, experienced a positive response to Pombiliti plus Opfolda, continues Opfolda, is not receiving another disease-modifying Pompe enzyme therapy, and dosing follows accepted sources.

    Revcovi initial and continuation therapy

    Covered when all applicable initial or continuation criteria are met.

    Initial therapy: ADA-SCID is diagnosed and ADA deficiency is confirmed by an accepted biochemical, metabolite, genetic, or TREC screening method; the patient is not a suitable HCT candidate, has failed HCT, or is awaiting HCT; dosing follows accepted clinical sources; and initial authorization is no more than 12 months.12 months
    Continuation therapy: The patient previously received elapegademase-lvlr, experienced a positive clinical response, dosing follows accepted clinical sources, and reauthorization is no more than 12 months.12 months

    Vimizim initial and continuation therapy

    Covered when all applicable initial or continuation criteria are met.

    Initial therapy: Morquio A syndrome is confirmed by deficient GALNS activity or GALNS molecular testing; clinical signs and symptoms are present; dosing follows accepted clinical sources; and initial authorization is no more than 12 months.12 months
    Continuation therapy: The patient previously received elosulfase alfa, experienced a positive clinical response, dosing follows accepted clinical sources, and reauthorization is no more than 12 months.12 months

    Xenpozyme initial and continuation therapy

    Covered when all applicable initial or continuation criteria are met.

    Initial therapy: ASMD type A/B or B is confirmed by deficient ASM activity or SMPD1 molecular testing; clinical signs and symptoms are present; Xenpozyme is not used for CNS manifestations; dosing follows accepted clinical sources; and initial authorization is no more than 12 months.12 months
    Continuation therapy: The patient previously received olipudase alfa-rpcp, experienced a positive clinical response, dosing follows accepted clinical sources, and reauthorization is no more than 12 months.12 months

    Avlayah Initial Therapy

    Covered when all of the following are met.

    Initial therapy

    • Confirmed MPS II

      • Enzyme testing: Iduronate 2-sulfatase deficiency in fibroblasts or leukocytes with normal activity of another sulfatase.
      • Molecular testing: Deletion or mutations in the iduronate 2-sulfatase gene are demonstrated.
    • Combination restriction: Avlayah is not used with Elaprase for MPS II.
    • Dosing follows FDA-approved labeling, nationally recognized compendia, or peer-reviewed medical literature.
    • Authorization duration: Initial authorization is no more than 12 months.12 months

    Avlayah Continuation Therapy

    Covered when all of the following are met.

    Continuation therapy

    • Prior treatment: The patient previously received tividenofusp alfa.
    • Positive clinical response: The patient experienced a positive response, such as improved hearing, functional capacity, neurological symptoms, spleen volume, or urine glycosaminoglycan excretion.
    • Combination restriction: Avlayah is not used with Elaprase for MPS II.
    • Dosing follows accepted clinical sources.
    • Authorization duration: Reauthorization is no more than 12 months.12 months

    Loargys Initial Therapy

    Covered when all of the following are met.

    Initial therapy

    • Confirmed arginase 1 deficiency

      • Enzyme testing: Arginase 1 enzyme activity is absent or deficient.
      • Genetic testing: Genetic variants are present in the ARG1 gene.
    • Clinical manifestations: Clinical signs and symptoms are present, such as loss of motor skills, intellectual disability, or developmental delay.
    • Dosing follows FDA-approved labeling, nationally recognized compendia, or peer-reviewed medical literature.
    • Authorization duration: Initial authorization is no more than 12 months.12 months

    Loargys Continuation Therapy

    Covered when all of the following are met.

    Continuation therapy

    • Prior treatment: The patient previously received pegzilarginase therapy.
    • Positive clinical response: The patient experienced a positive response, such as improved motor or pulmonary function.
    • Dosing follows FDA-approved labeling, nationally recognized compendia, or peer-reviewed medical literature.
    • Authorization duration: Reauthorization is no more than 12 months.12 months

    Avlayah and Elaprase must not be used together to treat MPS II (Hunter syndrome).

    Elfabrio and Fabrazyme must not be used in combination with another Fabry disease-modifying therapy, including the other listed enzyme therapy or Galafold.

    Lamzede is not covered when prescribed to treat central nervous system (CNS) manifestations of alpha-mannosidosis.

    Lamzede is not covered when prescribed to treat central nervous system (CNS) manifestations of alpha-mannosidosis.

    Lumizyme, Nexviazyme, and Pombiliti must not be used with another disease-modifying enzyme therapy for Pompe disease.

    Xenpozyme is not covered when prescribed to treat central nervous system (CNS) manifestations of acid sphingomyelinase deficiency (ASMD).

    Pombiliti must not be used with another disease-modifying enzyme therapy for Pompe disease, including Lumizyme or Nexviazyme.

    Avlayah must not be used in combination with Elaprase to treat MPS II.

    Applicable Codes and Clinical Thresholds

    Aldurazymemixed
    J1931Injection, laronidase, 0.1 mg
    E76.01Hurler's syndrome
    E76.02Hurler-Scheie syndrome
    E76.03Scheie's syndrome
    Avlayahmixed
    J1757Injection, tividenofusp alfa-eknm, 1 mg
    E76.1Mucopolysaccharidosis, type II
    Elaprasemixed
    J1743Injection, idursulfase, 1 mg
    E76.1Mucopolysaccharidosis, type II
    Elfabriomixed
    J2508Injection, pegunigalsidase alfa-iwxj, 1 mg
    E75.21Fabry (-Anderson) disease
    Fabrazymemixed
    J0180Injection, agalsidase beta, 1 mg
    E75.21Fabry (-Anderson) disease
    Kanumamixed
    J2840Injection, sebelipase alfa, 1 mg
    E75.5Other lipid storage disorders
    Lamzedemixed
    J0217Injection, velmanase alfa-tycv, 1 mg
    E77.1Defects in glycoprotein degradation
    Loargysmixed
    J1818Injection, pegzilarginase-nbln, 0.05 mg
    E27.21Argininemia
    Lumizymemixed
    J0221Injection, alglucosidase alfa, (Lumizyme), 10 mg
    E74.02Pompe disease
    Mepseviimixed
    J3397Injection, vestronidase alfa-vjbk, 1 mg
    E76.29Other mucopolysaccharidoses (includes Sly syndrome)
    Naglazymemixed
    J1458Injection, galsulfase, 1 mg
    E76.29Other mucopolysaccharidoses (includes Maroteaux-Lamy syndrome)
    Nexviazymemixed
    J0219Injection, avalglucosidase alfa-ngpt, 4 mg
    E74.02Pompe disease
    Nulibrymixed
    J1809Injection, fosdenopterin, 0.1 mg
    E72.10Disorders of sulfur-bearing amino-acid metabolism, unspecified
    E72.19Other disorders of sulfur-bearing amino-acid metabolism
    Nexviazyme Applicable CodesmixedCovered
    J0219Injection, avalglucosidase alfa-ngpt, 4 mg
    E74.02Pompe disease
    Nulibry Applicable CodesmixedCovered
    J1809Injection, fosdenopterin, 0.1 mg
    E72.10Disorders of sulfur-bearing amino-acid metabolism, unspecified
    E72.19Other disorders of sulfur-bearing amino-acid metabolism
    Pombiliti Applicable CodesmixedCovered
    J1203Injection, cipaglucosidase alfa-atga, 5 mg
    E74.02Pompe disease
    Revcovi Applicable CodesmixedCovered
    J3590Unclassified biologic
    D81.31Severe combined immunodeficiency due to adenosine deaminase deficiency
    Vimizim Applicable CodesmixedCovered
    J1322Injection, elosulfase alfa, 1 mg
    E76.210Morquio A mucopolysaccharidoses
    Xenpozyme Applicable CodesmixedCovered
    J0218Injection, olipudase alfa-rpcp, 1 mg
    E75.241Niemann-Pick disease type B; also applicable to ASMD type B and chronic visceral acid sphingomyelinase deficiency
    E75.244Niemann-Pick disease type A/B; ASMD type A/B and chronic neurovisceral acid sphingomyelinase deficiency
    Avlayah HCPCS CodeHCPCSCovered
    J1757Avlayah
    Avlayah ICD-10 Diagnosis CodeICD-10Covered
    E76.1Avlayah diagnosis code
    Loargys HCPCS CodeHCPCSCovered
    J1818Loargys
    Loargys ICD-10 Diagnosis CodeICD-10Covered
    E27.21Loargys diagnosis code
    Alpha-galactosidase A activity
    Threshold< 5% of mean
    ConditionFabry disease
    Testing specimensLeukocytes, dried blood spots, or serum analysis
    Alpha-mannosidase activity
    Threshold< 10% of the laboratory-specific normal mean
    ConditionAlpha-mannosidosis
    Confirmation alternativeMolecular genetic testing for mutations in the MAN2B1 gene
    Alpha-mannosidase enzyme activity
    Threshold< 10% of the lab-specific normal mean
    EnzymeAlpha-mannosidase
    Clinical requirementClinical signs and symptoms of alpha-mannosidosis must be present
    Infantile-onset Pompe enzyme activity
    Threshold< 1% of the lab-specific normal mean
    Testing specimenSkin fibroblasts
    Confirmation alternativeMolecular genetic testing for deletion or mutations in the GAA gene
    Late-onset Pompe enzyme activity
    Threshold< 40% of the lab-specific normal mean
    Testing specimensLymphocytes, fibroblasts, or muscle
    Confirmation alternativeMolecular genetic testing for deletion or mutations in the GAA gene
    MoCD type A clinical manifestation timing
    Timing requirementWithin the first 28 days after birth
    ConditionMolybdenum cofactor deficiency type A (MoCD type A)
    Examples of manifestationsSeizures, exaggerated startle response, high-pitched cry, hypotonia or hypertonia, and feeding difficulties
    Pombiliti minimum patient weight
    Minimum weight≥ 40 kg
    TherapyPombiliti with oral Opfolda (miglustat)
    PopulationPatients with late-onset Pompe disease
    GAA enzyme activity
    Threshold< 40% of the lab-specific normal mean
    ConditionLate-onset Pompe disease
    Testing specimensLymphocytes, fibroblasts, or muscle
    Patient weight for Pombiliti
    Required weight≥ 40 kg
    Treatment requirementPombiliti must be prescribed in combination with oral Opfolda (miglustat)
    Switching requirementCurrent enzyme replacement therapy must be stopped when the patient is not improving

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required for Initial Therapy

    Obtain prior authorization before initiating any listed enzyme-deficiency therapy. Coverage is contingent on the applicable drug-specific initial-therapy criteria, documented diagnosis, clinically appropriate dosing, and authorization time limits.

    • Applies to Aldurazyme, Avlayah, Elaprase, Elfabrio, Fabrazyme, Kanuma, Lamzede, Loargys, Lumizyme, Mepsevii, Naglazyme, Nexviazyme, Nulibry, Pombiliti, Revcovi, Vimizim, and Xenpozyme.
    • Submit diagnosis confirmation, required clinical findings, dosing rationale, and requested authorization duration.
    Documentation Required

    Document Continuation Therapy

    For continuation requests, document prior treatment with the requested product, a positive clinical response, dosing support, and the applicable renewal period.

    • Continuation criteria apply to each product-specific therapy.
    • Submit objective or clinically documented response measures when available.
    • Reauthorization is generally limited to no more than 12 months.
    Prior Authorization

    Authorization Period Limits

    Initial and renewal authorizations for these enzyme-deficiency therapies are generally limited to 12 months. Requests must support the applicable therapy phase and comply with labeled or otherwise supported dosing.

    • Initial authorization: no more than 12 months.
    • Renewal authorization: no more than 12 months.
    • Do not request an authorization period exceeding the policy limit.
    Step Therapy

    Pombiliti Requires Switching From Current ERT

    Before starting Pombiliti, attest that the patient is not improving on current late-onset Pompe ERT and that the current therapy will be stopped.

    • The current ERT may include Lumizyme or Nexviazyme.
    • The treatment-change attestation must accompany the initial request.
    Prior Authorization

    Pombiliti Initial and Renewal Requirements

    For Pombiliti, document all initial and renewal requirements, including weight, Opfolda use, clinical response, dosing, and the absence of prohibited concurrent Pompe therapy.

    • Initial therapy requires late-onset Pompe diagnosis, clinical signs and symptoms, weight of at least 40 kg, and prescribing Pombiliti with oral Opfolda (miglustat).
    • Continuation requires prior Pombiliti treatment, positive response to Pombiliti plus Opfolda, and continued combination use.
    • Initial and renewal authorizations are limited to 12 months.
    Prior Authorization

    Drug-Specific Prior Authorization: Avlayah and Loargys

    Avlayah and Loargys require drug-specific prior authorization with diagnosis confirmation, clinical documentation where applicable, dosing support, and phase-specific response documentation.

    • Avlayah: neurologic manifestations of Hunter syndrome (MPS II).
    • Loargys: hyperargininemia due to arginase 1 deficiency.
    • Initial and renewal authorizations are limited to 12 months.
    Documentation Required

    Failure of Current Pompe ERT

    Do not request Pombiliti as a continuation of ineffective current Pompe ERT without documenting the required treatment change.

    • Provider must attest that the patient is not improving on current Lumizyme or Nexviazyme therapy.
    • The current ERT must be stopped when Pombiliti is initiated.
    Documentation Required

    Aldurazyme Diagnostic Documentation

    For Aldurazyme, submit documentation confirming MPS I and the specific biochemical or molecular basis for the diagnosis.

    • Identify the Hurler, Hurler-Scheie, or Scheie MPS I variant.
    • Provide deficient or absent alpha-L-iduronidase activity in fibroblasts or leukocytes, or molecular confirmation of alpha-L-iduronidase gene mutations.
    Documentation Required

    MPS II Diagnostic Documentation

    For Avlayah or Elaprase, document MPS II using an accepted enzyme or molecular test and identify the treatment as appropriate for the requested product.

    • Provide deficient iduronate 2-sulfatase activity in fibroblasts or leukocytes with normal activity of another sulfatase, or molecular confirmation of deletion or mutations in the iduronate 2-sulfatase gene.
    • Avlayah is for neurologic manifestations of Hunter syndrome.
    Documentation Required

    Fabry Disease Documentation

    For Elfabrio or Fabrazyme, document Fabry disease with accepted enzyme-activity or molecular testing and provide relevant clinical manifestations.

    • Provide absent or deficient alpha-galactosidase A activity, including less than 5% of the mean where applicable, or molecular confirmation of galactosidase alpha gene mutations.
    • Document clinical signs or symptoms such as acroparesthesias, angiokeratomas, hypohidrosis or anhidrosis, renal disease, or exercise/temperature intolerance.
    Documentation Required

    Kanuma Diagnostic Documentation

    For Kanuma, confirm lysosomal acid lipase deficiency with an accepted dried-blood-spot enzyme test or molecular testing.

    • Document absent or deficient lysosomal acid lipase activity by dried blood spot testing, or mutations in the LIPA gene.
    • Identify the applicable phenotype, including Wolman disease or cholesteryl ester disease.
    Documentation Required

    Lamzede Diagnostic Documentation

    For Lamzede, confirm alpha-mannosidosis with enzyme or molecular testing and document the applicable clinical manifestations.

    • Provide alpha-mannosidase activity below 10% of the laboratory-specific normal mean, or MAN2B1 mutation testing.
    • Document manifestations such as hepatosplenomegaly, skeletal abnormalities, ataxia, intellectual disability, or hearing loss.

    Unsupported block type: documentation

    Documentation Required

    Diagnostic Confirmation Required

    Confirm the underlying diagnosis before requesting therapy and provide either the required enzyme-activity result or molecular confirmation.

    • Applicable conditions include alpha-mannosidosis, hyperargininemia, infantile- or late-onset Pompe disease, MPS VII, MPS VI, MoCD type A, and other product-specific deficiencies.
    • Use the product-specific laboratory or genetic standard in the policy.
    Documentation Required

    Document Clinical Signs and Symptoms

    For products requiring symptomatic disease documentation, describe current clinical signs and symptoms and relate them to the diagnosed disorder.

    • Examples include hepatosplenomegaly, skeletal abnormalities, ataxia, motor or intellectual impairment, cardiac or respiratory disease, weakness, seizures, and pulmonary limitations.
    • Do not rely on diagnosis coding alone when the policy requires clinical findings.
    Documentation Required

    Document Positive Treatment Response

    For continuation, provide evidence of meaningful clinical or laboratory benefit from the requested therapy and confirm that the patient remains an appropriate candidate.

    • Examples include improved respiratory, cardiac, pulmonary, motor, or functional status; reduced organ volume; or improved disease biomarkers.
    • A renewal without documented positive response may be denied.
    Documentation Required

    Dosing Support Required

    Support the requested dose with the FDA-approved labeling, nationally recognized compendia, or peer-reviewed medical literature.

    • Include weight-, age-, disease-, or regimen-specific dosing information when relevant.
    • This requirement applies to both initial and continuation requests.
    Documentation Required

    Revcovi Laboratory or Genetic Confirmation

    For Revcovi, document ADA-SCID and confirm adenosine deaminase deficiency by an accepted laboratory, genetic, or screening method.

    • Accepted support includes deficient or absent ADA, elevated erythrocyte dATP, decreased erythrocyte ATP, biallelic ADA1 mutations, or positive T-cell receptor excision-circle screening.
    • Also document that the patient is not suitable for HCT, has failed HCT, or is awaiting HCT.
    Documentation Required

    Clinical Findings and Response

    For Revcovi and Xenpozyme, document the required clinical findings and, for renewal, objective or clinical response to therapy.

    • Xenpozyme requires ASMD type A/B or B, clinical signs such as hepatosplenomegaly or abnormal pulmonary function, and exclusion of CNS treatment.
    • Revcovi renewal may include normalized plasma ADA activity, improved dATP levels, or improved disease symptoms.
    Documentation Required

    Pombiliti Treatment-Change Attestation

    The Pombiliti request must include a provider attestation that the patient is not improving on current Pompe ERT and that the ERT will be discontinued.

    • Attestation applies to current Lumizyme or Nexviazyme therapy.
    • Pombiliti must be used with oral Opfolda (miglustat).
    Documentation Required

    Pompe Regimen and Dosing Support

    For Pombiliti and related Pompe therapies, document the prescribed regimen, including Opfolda when required, and support dosing under accepted clinical standards.

    • Pombiliti requires combination use with Opfolda.
    • Document the requested dose and schedule in accordance with FDA labeling, compendia, or peer-reviewed literature.
    Documentation Required

    Avlayah Diagnosis Confirmation

    For Avlayah, confirm MPS II by enzyme testing or molecular genetic testing and document the neurologic manifestation being treated.

    • Provide deficient iduronate 2-sulfatase activity with normal activity of another sulfatase, or deletion or mutation testing of the iduronate 2-sulfatase gene.
    • Avlayah is intended for neurologic manifestations of Hunter syndrome.
    Documentation Required

    Loargys Diagnosis Confirmation

    For Loargys, confirm hyperargininemia due to arginase 1 deficiency by enzyme activity testing or ARG1 genetic testing and document clinical manifestations.

    • Provide absent or deficient arginase 1 activity, or pathogenic genetic variants in ARG1.
    • Document findings such as loss of motor skills, intellectual disability, or developmental delay.
    Documentation Required

    Avlayah and Loargys Continuation Response

    Renewal requests for Avlayah or Loargys must document prior treatment and a positive response to the requested product.

    • Avlayah response examples include improved hearing, function, neurologic symptoms, spleen volume, or urinary glycosaminoglycan excretion.
    • Loargys response examples include improved motor or pulmonary function.
    Denial Risk

    Do Not Combine Avlayah With Elaprase

    Do not use Avlayah and Elaprase together for treatment of MPS II.

    • Requests showing concurrent Avlayah and Elaprase may be denied.
    • Select and document the clinically appropriate MPS II therapy.
    Denial Risk

    Avoid Combination Fabry Therapy

    Do not combine Elfabrio or Fabrazyme with another disease-modifying Fabry therapy.

    • Prohibited combinations include the other Fabry enzyme therapy and Galafold (migalastat), as specified for the requested product.
    • Document that the patient is not receiving a prohibited combination.
    Denial Risk

    Lamzede CNS Use Excluded

    Lamzede is not covered when prescribed to treat central nervous system manifestations of alpha-mannosidosis.

    • Document that the requested use is not for CNS manifestations.
    • Requests for excluded CNS use may be denied.
    Prior Authorization

    Authorization Criteria and Time Limits

    Each product requires initial and continuation criteria, supported dosing, and authorization periods no longer than 12 months.

    • Initial requests require diagnosis confirmation and any required clinical findings or restrictions.
    • Renewals require prior treatment and positive response unless the product-specific criteria state otherwise.
    • Do not omit product-specific exclusions or time limits.
    Denial Risk

    Lamzede Diagnostic or CNS-Use Failure

    Lamzede may be denied when alpha-mannosidosis is not confirmed, required clinical findings are absent, or the request is for CNS manifestations.

    • Provide enzyme or MAN2B1 genetic confirmation.
    • Document qualifying signs and symptoms.
    • Confirm the requested treatment is not for CNS manifestations.
    Denial Risk

    Prohibited Pompe Therapy Combinations

    Do not combine Lumizyme or Nexviazyme with another disease-modifying Pompe enzyme therapy, including Pombiliti.

    • Prohibited examples include Lumizyme with Nexviazyme or Pombiliti, and Nexviazyme with Lumizyme or Pombiliti.
    • Pombiliti must be paired with Opfolda, not another Pompe ERT.
    Denial Risk

    Pombiliti Eligibility Requirements

    Pombiliti eligibility requires late-onset Pompe disease, qualifying clinical findings, weight of at least 40 kg, failure to improve on current ERT, discontinuation of that ERT, and combination use with Opfolda.

    • The prescribed regimen must include oral Opfolda (miglustat).
    • The provider must attest to the treatment change.
    Denial Risk

    Continuation Criteria Must Be Met

    A continuation request may be denied when prior treatment, positive clinical response, dosing support, or required regimen documentation is missing.

    • Document ongoing benefit using appropriate clinical or laboratory measures.
    • Confirm continued compliance with product-specific restrictions.
    Denial Risk

    Concurrent Pompe Enzyme Therapy Prohibited

    Do not administer Pombiliti concurrently with Lumizyme, Nexviazyme, or another disease-modifying Pompe enzyme therapy.

    • Pombiliti is prescribed with Opfolda, not with another Pompe ERT.
    • Concurrent Pompe disease enzyme therapy may result in denial.
    Denial Risk

    CNS Treatment Exclusion

    Xenpozyme is not covered for treatment of central nervous system manifestations of ASMD.

    • Document that the requested treatment targets qualifying non-CNS ASMD manifestations, such as hepatosplenomegaly, liver abnormalities, dyslipidemia, or pulmonary dysfunction.
    Denial Risk

    Failure to Meet Therapy Criteria

    Requests may be denied when the patient does not meet the product-specific diagnosis, clinical findings, response, dosing, combination-therapy, or authorization-period requirements.

    • For Pombiliti, include current-ERT failure, treatment discontinuation, weight, Opfolda use, and response documentation as applicable.
    • For Revcovi, include ADA-SCID confirmation and HCT status.
    • For Xenpozyme, include ASMD confirmation and non-CNS treatment intent.
    Denial Risk

    Avlayah and Elaprase Combination Excluded

    Do not use Avlayah and Elaprase concurrently for MPS II treatment.

    • Avlayah requests must explicitly document that Elaprase is not being used in combination.
    • Elaprase requests must explicitly document that Avlayah is not being used in combination.
    Denial Risk

    Drug-Specific Criteria Not Met

    Avlayah or Loargys may be denied when drug-specific diagnostic, clinical, continuation, dosing, or combination requirements are not documented.

    • Avlayah requires MPS II confirmation and neurologic manifestations; it may not be combined with Elaprase.
    • Loargys requires ARG1-related hyperargininemia and qualifying clinical findings.
    • Renewal requires prior treatment and positive response.
    Denial Risk

    Authorization Period Exceeds Limit

    Do not request an initial or renewal authorization for Avlayah or Loargys longer than 12 months.

    • Initial authorization: no more than 12 months.
    • Reauthorization: no more than 12 months.
    • Requests exceeding the limit may be denied or reduced.

    Policy Background

    This policy addresses medical therapies for rare inherited enzyme deficiencies, including mucopolysaccharidoses, Fabry disease, lysosomal acid lipase deficiency, and alpha-mannosidosis. Coverage generally requires laboratory or molecular confirmation of the underlying deficiency, disease-specific clinical manifestations when specified, dosing consistent with accepted clinical sources, and evidence of a positive clinical response for continuation therapy.

    Disease and Therapy Definitions

    MPS I definition
    DefinitionMucopolysaccharidosis I
    Included variantsHurler, Hurler-Scheie, and Scheie variants
    Associated therapyAldurazyme (laronidase) is medically necessary for the treatment of MPS I when applicable criteria are met
    MPS II definition
    DefinitionMucopolysaccharidosis type II
    Also calledHunter syndrome
    Associated therapiesAvlayah and Elaprase are addressed for MPS II
    LAL-D definition
    DefinitionLysosomal acid lipase deficiency
    Included conditionsWolman disease and cholesteryl ester disease
    ConfirmationDried blood spot enzyme testing or molecular genetic testing involving LIPA
    Late-onset Pompe disease definition
    DefinitionLate-onset Pompe disease
    Enzyme confirmationDeficient acid alpha-glucosidase activity below 40% of the lab-specific normal mean
    Genetic confirmationDeletion or mutations in the GAA gene
    ADA-SCID definition
    DefinitionAdenosine deaminase severe combined immune deficiency
    AbbreviationADA-SCID
    Confirmation methodsADA deficiency by biochemical, metabolite, genetic, or T-cell receptor excision circle screening findings
    Morquio A syndrome definition
    DefinitionMucopolysaccharidosis type IVA
    Also calledMPS IVA or Morquio A syndrome
    ConfirmationDeficient GALNS enzyme activity or mutations in the GALNS gene
    ASMD definition
    DefinitionAcid sphingomyelinase deficiency
    Included typesType A/B or type B disease
    ConfirmationDeficient ASM enzyme activity or mutations in the SMPD1 gene
    Non-central nervous system manifestations of ASMD
    DefinitionAcid sphingomyelinase deficiency with disease manifestations outside the central nervous system
    AbbreviationNon-CNS manifestations of ASMD
    Relevant therapyXenpozyme is evaluated for non-central nervous system manifestations of ASMD
    Medical therapies for enzyme deficiencies
    DefinitionEnzyme replacement or related therapies used to treat inherited deficiencies
    Conditions addressedLysosomal, metabolic, or immune-system enzyme deficiencies
    ExamplesTherapies covered in this policy include Aldurazyme, Fabrazyme, Lumizyme, Revcovi, Vimizim, and Xenpozyme

    Initial Therapy Requirements

    Aldurazyme initial therapy

    Covered when all of the following are met.

    Aldurazyme initial therapy: MPS I subtype is confirmed and alpha-L-iduronidase deficiency or molecular confirmation is documented; dosing follows accepted clinical sources; initial authorization is no more than 12 months.12 months

    Avlayah initial therapy

    Covered when all of the following are met.

    Avlayah initial therapy: MPS II is confirmed by enzyme or molecular testing; Avlayah is not used with Elaprase; dosing follows accepted clinical sources; initial authorization is no more than 12 months.12 months

    Elaprase initial therapy

    Covered when all of the following are met.

    Elaprase initial therapy: MPS II is confirmed by enzyme or molecular testing; Elaprase is not used with Avlayah; dosing follows accepted clinical sources; initial authorization is no more than 12 months.12 months

    Elfabrio initial therapy

    Covered when all of the following are met.

    Elfabrio initial therapy: Fabry disease is confirmed by alpha-galactosidase A deficiency or molecular testing; clinical signs and symptoms are present; Elfabrio is not combined with another Fabry disease-modifying therapy; dosing follows accepted clinical sources; initial authorization is no more than 12 months.12 months

    Fabrazyme initial therapy

    Covered when all of the following are met.

    Fabrazyme initial therapy: Fabry disease is confirmed by alpha-galactosidase A deficiency or molecular testing; clinical signs and symptoms are present; Fabrazyme is not combined with another Fabry disease-modifying therapy; dosing follows accepted clinical sources; initial authorization is no more than 12 months.12 months

    Kanuma initial therapy

    Covered when all of the following are met.

    Kanuma initial therapy: LAL-D, Wolman disease, or cholesteryl ester disease is confirmed by deficient lysosomal acid lipase activity on dried blood spot testing or LIPA molecular testing; dosing follows accepted clinical sources; initial authorization is no more than 12 months.12 months

    Lamzede initial therapy

    Covered when all of the following are met.

    Lamzede initial therapy: Alpha-mannosidosis is confirmed by alpha-mannosidase deficiency or MAN2B1 molecular testing; clinical signs and symptoms are present; Lamzede is not used for CNS manifestations; dosing follows accepted clinical sources; initial authorization is no more than 12 months.12 months

    General initial therapy requirements

    Covered when all of the following are met.

    General initial requirements: The applicable disease is confirmed by specified enzyme activity or molecular testing; required clinical signs and symptoms are present when specified; dosing follows FDA-approved labeling, nationally recognized compendia, or peer-reviewed medical literature; and initial authorization is no more than 12 months. Additional product-specific requirements, including CNS-use, non-combination, switching, weight, or Opfolda requirements, must also be met.12 months

    Pombiliti initial therapy

    Covered when all of the following are met.

    Pombiliti initial therapy: Late-onset Pompe disease is confirmed by GAA deficiency or GAA molecular testing; clinical signs and symptoms are present; current ERT is not improving the patient and will be stopped; weight is at least 40 kg; Pombiliti is prescribed with oral Opfolda; no other disease-modifying Pompe enzyme therapy is used concurrently; dosing follows accepted clinical sources; and initial authorization is no more than 12 months.GAA activity < 40%; weight ≥ 40 kg; 12 months

    Revcovi initial therapy

    Covered when all of the following are met.

    Revcovi initial therapy: ADA-SCID and ADA deficiency are confirmed by an accepted biochemical, metabolite, genetic, or TREC method; the patient is not a suitable HCT candidate, has failed HCT, or is awaiting HCT; dosing follows accepted clinical sources; and initial authorization is no more than 12 months.12 months

    Vimizim initial therapy

    Covered when all of the following are met.

    Vimizim initial therapy: Morquio A syndrome is confirmed by deficient GALNS activity or GALNS molecular testing; clinical signs and symptoms are present; dosing follows accepted clinical sources; and initial authorization is no more than 12 months.12 months

    Xenpozyme initial therapy

    Covered when all of the following are met.

    Xenpozyme initial therapy: ASMD type A/B or B is confirmed by deficient ASM activity or SMPD1 molecular testing; clinical signs and symptoms are present; Xenpozyme is not used for CNS manifestations; dosing follows accepted clinical sources; and initial authorization is no more than 12 months.12 months

    Avlayah and Loargys initial therapy

    Covered when the applicable product-specific criteria are met.

    Initial therapy

    • Avlayah: MPS II is confirmed by enzyme or molecular testing; Avlayah is not used with Elaprase; dosing follows accepted clinical sources; and initial authorization is no more than 12 months.12 months
    • Loargys: Arginase 1 deficiency is confirmed by enzyme activity or ARG1 genetic testing; clinical signs or symptoms are present; dosing follows accepted clinical sources; and initial authorization is no more than 12 months.12 months

    Continuation and Reauthorization Requirements

    Aldurazyme continuation

    Covered when all of the following are met.

    Aldurazyme continuation: Prior laronidase treatment and positive clinical response are documented; dosing follows accepted clinical sources; reauthorization is no more than 12 months.12 months

    Avlayah continuation

    Covered when all of the following are met.

    Avlayah continuation: Prior tividenofusp alfa treatment and positive clinical response are documented; Avlayah is not used with Elaprase; dosing follows accepted clinical sources; reauthorization is no more than 12 months.12 months

    Elaprase continuation

    Covered when all of the following are met.

    Elaprase continuation: Prior idursulfase treatment and positive clinical response are documented; Elaprase is not used with Avlayah; dosing follows accepted clinical sources; reauthorization is no more than 12 months.12 months

    Elfabrio continuation

    Covered when all of the following are met.

    Elfabrio continuation: Prior pegunigalsidase alfa treatment and positive clinical response are documented; Elfabrio is not combined with another Fabry disease-modifying therapy; dosing follows accepted clinical sources; reauthorization is no more than 12 months.12 months

    Fabrazyme continuation

    Covered when all of the following are met.

    Fabrazyme continuation: Prior agalsidase beta treatment and positive clinical response are documented; Fabrazyme is not combined with another Fabry disease-modifying therapy; dosing follows accepted clinical sources; reauthorization is no more than 12 months.12 months

    Kanuma continuation

    Covered when all of the following are met.

    Kanuma continuation: Prior sebelipase alfa treatment and positive clinical response are documented; dosing follows accepted clinical sources; reauthorization is no more than 12 months.12 months

    Lamzede continuation

    Covered when all of the following are met.

    Lamzede continuation: Prior velmanase alfa treatment and positive clinical response are documented; dosing follows accepted clinical sources; reauthorization is no more than 12 months.12 months

    General continuation requirements

    Covered when all of the following are met.

    General continuation requirements: Prior treatment with the requested therapy and a positive clinical response are documented; dosing follows FDA-approved labeling, nationally recognized compendia, or peer-reviewed medical literature; and reauthorization is no more than 12 months.12 months

    Pombiliti continuation

    Covered when all of the following are met.

    Pombiliti continuation: The patient previously received Pombiliti, experienced a positive response to Pombiliti plus Opfolda, continues Opfolda, is not receiving another disease-modifying Pompe enzyme therapy, dosing follows accepted clinical sources, and reauthorization is no more than 12 months.12 months

    Revcovi continuation

    Covered when all of the following are met.

    Revcovi continuation: The patient previously received elapegademase-lvlr, experienced a positive clinical response, dosing follows accepted clinical sources, and reauthorization is no more than 12 months.12 months

    Vimizim continuation

    Covered when all of the following are met.

    Vimizim continuation: The patient previously received elosulfase alfa, experienced a positive clinical response, dosing follows accepted clinical sources, and reauthorization is no more than 12 months.12 months

    Xenpozyme continuation

    Covered when all of the following are met.

    Xenpozyme continuation: The patient previously received olipudase alfa-rpcp, experienced a positive clinical response, dosing follows accepted clinical sources, and reauthorization is no more than 12 months.12 months

    Avlayah and Loargys continuation therapy

    Covered when the applicable product-specific continuation criteria are met.

    Continuation therapy

    • Avlayah: Prior tividenofusp alfa treatment and positive clinical response are documented; Avlayah is not used with Elaprase; dosing follows accepted clinical sources; reauthorization is no more than 12 months.12 months
    • Loargys: Prior pegzilarginase treatment and positive clinical response are documented; dosing follows accepted clinical sources; reauthorization is no more than 12 months.12 months

    Treatment Switching Requirements

    StepCurrent therapy requirementRequired change
    1Patient is not improving on current late-onset Pompe disease enzyme replacement therapy, such as Lumizyme or Nexviazyme.Stop the current ERT and initiate Pombiliti in combination with oral Opfolda (miglustat).

    Authorization Period Limits

    Drug-specific initial authorization and reauthorization limit
    Initial authorizationNo more than 12 months
    ReauthorizationNo more than 12 months
    Applies toTherapies with stated drug-specific initial and continuation criteria
    Initial or continuation authorization period limit
    Authorization periodNo more than 12 months
    Initial therapyPrior authorization is required
    Continuation therapyReauthorization is required and requires prior treatment with a positive clinical response
    Pombiliti, Revcovi, Vimizim, and Xenpozyme authorization period limit
    Initial authorizationNo more than 12 months
    ReauthorizationNo more than 12 months
    Affected therapiesPombiliti, Revcovi, Vimizim, and Xenpozyme